US Generic Drug Tariffs – Know About Phased Plan, Impact on India 

US Generic Drug Tariffs – Know About Phased Plan, Impact on India 

Why in News?

Recently, the United States announced phased US Generic Drug Tariffs on imported generic drugs, allowing a two-year duty-free window before imposing tariffs.

Highlights of US Generic Drug Tariffs Plan

• Announcement: The United States announced a phased tariff roadmap for imported generic drugs on 21 July 2026, describing it as a long-term industrial policy.
  • Operational details regarding customs procedures, implementation rules, and exemptions are yet to be officially notified.
• Need: The proposal is intended to encourage manufacturers to relocate pharmaceutical production to the US.
  • Generic drugs account for more than 90% of all prescriptions dispensed in the US but make up less than 13% of total prescription drug costs.
  • The US wants to strengthen drug supply-chain resilience, and enhance national health security.
• Tariff Timeline: The plan follows a three-stage schedule.
  • Phase I: 0% tariff from 1 August 2026 for two years. 
  • Phase II: 100% tariff for the following one year beginning August 2028. 
  • Phase III: 200% tariff thereafter, with no end date announced. 
• Coverage: The plan targets generic drugs, with separate, different frameworks applicable to patented or branded medications.
  • The announcement does not yet provide detailed product-level exemptions or a finalized list of affected tariff lines.
• Transition Window: The two-year zero-duty period serves as a transition window, allowing pharmaceutical companies time to shift manufacturing, expand US facilities, and modify supply chains.
• Penalty Structure: Non-compliance after 2028 triggers punitive, and high-level duties.
  • Penalties can be bypassed by companies that invest directly in US-based manufacturing infrastructure.
• Global Impact: The proposal could significantly alter global generic drug supply chains.
  • Countries heavily dependent on pharmaceutical exports may face competitive pressure. 
  • Steep tariffs could eventually increase procurement costs, affect medicine affordability, and create temporary supply disruptions.

Impact of US Drug Tariffs on India 

• Dependence on US Export Market: The United States remains India’s largest pharmaceutical export destination, accounting for about 38% of India’s pharmaceutical exports.
  • India exported around US$9.7 billion worth of pharmaceutical products to the US in 2025, making the sector particularly sensitive to changes in US trade policy.
  • India is supplying 47% of generic prescriptions in the US, which saved their healthcare system over $219 billion in 2022 and $1.3 trillion over the past decade.
• Revenue Exposure of Indian Pharma: Several leading Indian companies derive a significant share of revenue from the US generic medicines market.
  • Companies like Cipla and Dr. Reddy’s dominate the market in therapeutic categories, including mental health, hypertension, high cholesterol, infectious diseases, and diabetes.
  • The proposed tariff could materially affect export earnings, especially for firms with concentrated US exposure. 
• Pressure on Generic Drug Pricing: Indian generic medicines compete primarily through low-cost pricing.
  • A steep tariff would substantially raise the landed cost in the US, reducing pricing flexibility and making it difficult for exporters to retain market share.
• Company-wise Impact Will Differ: The impact will not be uniform. Companies already operating manufacturing facilities in the United States or possessing diversified global production networks are expected to face lower disruption.
• Supply Chain Reorientation: Indian exporters may increasingly diversify towards Europe, Africa, Latin America and emerging Asian markets, while expanding high-value product portfolios to reduce dependence on a single export destination. 
• Long-Term Industry Response: The proposed tariff plan is expected to accelerate investments in complex generics, biosimilars, specialty formulations, automation and supply-chain resilience.
  • Over the medium term, Indian firms are likely to focus on innovation-led growth and geographic diversification.

India’s Generic Medicines Market 

• Global Leadership: India is the world’s largest supplier of generic medicines by volume, contributing nearly 20% of global generic drug supply.
  • The country manufactures around 60,000 generic products across 60 therapeutic categories, earning the title “Pharmacy of the World.” 
  • This large production base strengthens India’s resilience despite external trade shocks.
• Strong Domestic Market: India’s pharmaceutical market was valued at about US$50 billion (FY 2023–24) and is projected to reach nearly US$130 billion by 2030.
  • India’s generic drugs market was valued at around US$30 billion in 2025 and is projected to reach US$53.5 billion by 2034, growing at a 6.42% CAGR (2026–2034).
• Manufacturing Scale: India possesses one of the world’s largest pharmaceutical manufacturing ecosystems, supported by thousands of WHO-GMP and USFDA-compliant facilities.
  • India exported US$30.5 billion worth of pharmaceuticals in 2024–25, nearly 16 times higher than in 2000–01. 
  • Indian companies are increasingly investing in complex generics, injectable formulations, biosimilars and specialty medicines.
  • India’s biosimilars market is estimated to reach US$12 billion, supported by nearly 22% CAGR. 
• API Manufacturing: India is the third-largest global producer of Active Pharmaceutical Ingredients (APIs).
  • It contributes around 8% of global API output and manufactures over 500 APIs, including 57% of WHO-prequalified APIs. 
  • India remains dependent on imports for several products.
• Regulated Markets: Indian pharmaceutical exports now reach 191 countries, with nearly 50% destined for highly regulated markets such as the US and Europe.
  • India’s pharmaceutical exports reached $30.47 billion in 2024–25 and grew to over $31 billion in 2025–26. 
  • Nicaragua has also officially recognized the Indian Pharmacopoeia standards, opening new regulatory doors across Latin America.
• Government Policies: Government initiatives such as Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) have expanded domestic acceptance of generic medicines.
  • It offers quality drugs at 50–90% lower prices than branded medicines. 
  • Schemes such as the Production Linked Incentive (PLI) programme promoting Bulk Drug Parks aim to strengthen domestic manufacturing.
    • Three Bulk Drug Parks (Gujarat, Andhra Pradesh, and Himachal Pradesh) are being developed under the Department of Pharmaceuticals‘ ₹3,000 crore central grant-in-aid scheme.

FAQs:

Disclaimer: Information in this article is based on official announcements and public records. Regulations and implementation details may evolve over time.